Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development and Validation of the ChemoResist Signature Precisely Predictive of Chemotherapy Sensitivity in Resected Pancreatic Ductal Adenocarcinoma

NCT06461598 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06461598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06461598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development and Validation of the ChemoResist Signature Precisely Predictive of Chemotherapy Sensitivity in Resected Pancreatic Ductal Adenocarcinoma
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Completed
Start date
January 1, 2018
Completion date
May 31, 2021
Enrollment
365 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer